© The Financial Times Ltd 2015 FT and 'Financial Times' are trademarks of The Financial Times Ltd.
As of Apr 17, 2015, the consensus forecast amongst 22 polled investment analysts covering Kalbe Farma Tbk PT advises investors to hold their position in the company. This has been the consensus forecast since the sentiment of investment analysts deteriorated on Feb 14, 2015. The previous consensus forecast advised that Kalbe Farma Tbk PT would outperform the market.
|Last year||3 months ago||2 months ago||4 weeks ago||Latest|
The 18 analysts offering 12 month price targets for Kalbe Farma Tbk PT have a median target of 1,855, with a high estimate of 2,200 and a low estimate of 1,090. The median estimate represents a -1.07 % decrease from the last price of 1,875. View Full Financials
In 2013, Kalbe Farma Tbk PT reported a dividend of 17.00 IDR, which represents a 10.53 % decrease from last year. The 16 analysts covering the company expect dividends of 18.91 IDR for the upcoming fiscal year, an increase of 11.22%. View Full Financials
|Div growth (TTM)||-10.53 %|
On Jul 25, 2014, Kalbe Farma Tbk PT reported 2nd quarter 2014 earnings of 10.00 per share. This result under-performed the 11.97 expectation of the one analyst following the company but was the same as last year's 2nd quarter results.
The next earnings announcement is expected on Mar 30, 2015. View Full Interim Financials
|Average growth rate||+1.48 %|
Kalbe Farma Tbk PT reported annual 2013 earnings of 41.00 per share on Mar 27, 2014. View Full Annual Financials
|Average growth rate||+21.12 %|
PT Kalbe Farma Tbk had 3rd quarter 2014 revenues of 4.38bn. This missed the 4.47bn estimate of the one analyst following the company. This was 1.52% above the prior year's 3rd quarter results. View Full Interim Financials
|Average growth rate||+2.56 %|
PT Kalbe Farma Tbk had revenues for the full year 2013 of 16.00bn. This was 17.35% above the prior year's results. View Full Annual Financials
|Average growth rate||+15.48 %|